CRNX MEXC RealStocks
Own real CRNX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-14 04:25:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
Crinetics Pharmaceuticals, Inc. (CRNX) last closed at $-- as of --, -- from the previous close of $--.
During the latest regular trading session, CRNX traded between $-- and $--, with a volume of -- shares. The closing price was -- and --.
Over the past seven days, Crinetics Pharmaceuticals, Inc. (CRNX) moved from $84.70 to $84.95, representing a gain of 0.30% ($0.25).
The stock traded between $84.69 and $85.01 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 2.15 million shares, down versus the previous seven-day period, indicating lower trading activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 594 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Crinetics Pharmaceuticals, Inc. (CRNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CRNX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CRNX shares and USD.
CRNX Shares to USD
1.00 CRNX shares = 0 USD
Calculations are estimates based on the latest available price and are for reference only.